XRad Therapeutics Announces First Patient Dosed in Phase 1a Clinical Trial of XRD-0394 for Metastatic, Locally-Advanced or Recurrent Solid Tumors
25 août 2021 07h30 HE
|
XRad Therapeutics, Inc.
- Study to evaluate the safety and tolerability of XRD-0394 in combination with palliative radiation therapy - Major milestone for the company with first asset reaching clinical development ...
The glycosylation analysis services market is projected to reach nearly USD 2.5 billion by 2030, growing at an annualized rate of over 20%, claims Roots Analysis
18 août 2021 09h30 HE
|
Roots Analysis
London, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “Glycosylation Analysis Services Market, 2021 – 2030” report to its list of offerings. Profiling and in-depth...
Rubius Therapeutics Announces First Patient Dosed with RTX-240 in Combination with KEYTRUDA® (pembrolizumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of Advanced Solid Tumors
23 juin 2021 16h01 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., June 23, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Checkpoint Kinase Inhibitor Pipeline Analysis: Key Pharma Companies, and Emerging Therapies Offering New Horizons in Cancer Care
06 mai 2021 20h15 HE
|
DelveInsight Business Research LLP
Los Angeles, USA, May 06, 2021 (GLOBE NEWSWIRE) -- Checkpoint Kinase Inhibitor Pipeline Analysis: Key Pharma Companies, and Emerging Therapies Offering New Horizons in Cancer Care Several...
Rubius Therapeutics Presents Initial Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors at the American Association of Cancer Research Virtual Annual Meeting
09 avr. 2021 08h00 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., April 09, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Cello Therapeutics’ Platelet Membrane-Coated Nanoparticles Offer a Novel Platform for the Delivery of Immunotherapy in Cancer Treatment
31 mars 2021 22h57 HE
|
Cello Therapeutics, Inc.
SAN DIEGO, March 31, 2021 (GLOBE NEWSWIRE) -- Solid tumors comprise about 90% of all newly diagnosed cancer cases and cancer deaths according to an annual report from the National Cancer Institute....
Rubius Therapeutics Reports Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors, Demonstrating Single-Agent Activity
15 mars 2021 07h39 HE
|
Rubius Therapeutics
RTX-240 Generated Partial Responses in Metastatic Anal Cancer and Metastatic Uveal Melanoma Patients; No DLTs or Related Grade 3/4 Adverse Events RTX-240 Promoted Trafficking of NK and T Cells into...
Rubius Therapeutics to Present Initial Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors at the American Association of Cancer Research Virtual Annual Meeting
10 mars 2021 16h30 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Cend Therapeutics and Qilu Pharmaceutical Announce Partnership
16 févr. 2021 08h00 HE
|
Cend Therapeutics Inc.
SAN DIEGO and JINAN, China, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Cend Therapeutics, Inc., a clinical-stage biotech company, and Qilu Pharmaceutical, a major Chinese pharmaceutical company, announced...
Autolus Therapeutics announces publication of new AUTO6 Phase 1 data in childhood neuroblastoma in Science Translational Medicine
30 nov. 2020 07h00 HE
|
Autolus Therapeutics plc
- Findings from the Phase 1 study provide evidence that AUTO6 induces clinical activity in this solid tumor setting without inducing on-target off-tumor toxicity - AUTO6NG builds on this approach...